Bayer Reports Positive Safety Data on Parkinson's Disease Drug

Bayer Ag (BAYRY) and its wholly owned subsidiary BlueRock Therapeutics LP announced positive 24-month data from an early-stage study on experimental candidate bemdaneprocel (BRT-DA01). Bemdaneprocel, an investigational cell therapy, is being evaluated for the treatment of Parkinson's disease. exPDite is a multi-center, multi-site, open-label, non-randomized, non-controlled phase I study. Data from the phase I exPDite study at 24 months continue to show a favorable safety profile in all 12 participants in th ...